46992 Federal Register / Vol. 86, No. 160 / Monday, August 23, 2021 / Rules and Regulations 

1Under the CAA, certain ODS are classified as 

‘‘class I’’ substances. Class I substances are listed in 

Appendix A to 40 CFR part 82, subpart A. 

2 Decision XXXI/5: Laboratory and Analytical 

Uses, available online at: https://ozone.unep.org/ 

treaties/montreal-protocol/meetings/thirty-firstmeeting-parties/decisions/decision-xxxi5. 

3Consumption is defined in § 82.3 as ‘‘production 

plus imports minus exports of a controlled 

substance (other than transhipments, or used 

controlled substances).’’ 

4These 2018 data are available in the docket to 

this rule as well as on the Montreal Protocol’s 

Ozone Secretariat’s Data Centre web page: https:// 

ozone.unep.org/countries/data-table. 

5At the time of publication for the proposed 

rulemaking, the 2019 data were not yet available, 

but can now be found on the Montreal Protocol’s 

Ozone Secretariat’s Data Centre web page: https:// 

ozone.unep.org/countries/data-table. Data specific 

to the United States’ amounts consumed for 

laboratory and analytical uses, including 2019 data, 

can be found on this web page: https://

ozone.unep.org/countries/profile/usa. These data 

have been added to the docket for this rulemaking. 

this section was approved by the 

Director of the Federal Register Office in 

accordance with U.S.C. 552(a)(1) and 1 

CFR part 51. The material is available 

from the sources identified elsewhere in 

this paragraph. It may be inspected or 

obtained from the EPA Region 2 Office, 

290 Broadway, 25th Floor, New York, 

New York 10007–1866, 212–637–3378. 

Copies may be inspected at the National 

Archives and Records Administration 

(NARA). For information on the 

availability of this material at NARA, 

email fr.inspection@nara.gov or go to: 

www.archives.gov/federal-register/cfr/ 

ibr-locations.html. 

(2) State of New York, Department of 

State, Albany, New York 12231; https:// 

dos.ny.gov/state-register. 

(i) 6 NYCRR Part 208: Official 

Compilation of (New York) Codes, Rules 

and Regulations; Title 6— 

Environmental Conservation; Part 208— 

Landfill Gas Collection and Control 

Systems for Certain Municipal Solid 

Waste Landfills, effective September 4, 

2019. 

(ii) [Reserved] 

[FR Doc. 2021–17292 Filed 8–20–21; 8:45 am] 

BILLING CODE 6560–50–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

40 CFR Part 82 

[EPA–HQ–OAR–2020–0084; FRL–7810–02– 

OAR] 

RIN 2060–AU80 

Protection of Stratospheric Ozone: 

Extension of the Laboratory and 

Analytical Use Exemption for Essential 

Class I Ozone-Depleting Substances 

AGENCY: Environmental Protection 

Agency. 

ACTION: Final rule. 

SUMMARY: The Environmental Protection 

Agency is taking final action to revise 

regulations governing the production 

and import of class I ozone-depleting 

substances in the United States to 

indefinitely extend the global essential 

laboratory and analytical use 

exemption. This exemption currently 

expires on December 31, 2021, and this 

final action allows for continued 

production and import of class I 

substances in the United States solely 

for laboratory and analytical uses that 

have not been identified by the 

Environmental Protection Agency as 

nonessential. This final action is taken 

under the Clean Air Act, and is 

consistent with a decision by the Parties 

to the Montreal Protocol on Substances 

that Deplete the Ozone Layer to extend 

the global laboratory and analytical use 

exemption indefinitely beyond 2021. 

The proposed rule associated with this 

final action was published on August 7, 

2020, and we received no adverse 

comments. 

DATES: This final rule is effective on 

September 22, 2021. 

ADDRESSES: The Environmental 

Protection Agency (EPA) has established 

a docket for this action under Docket ID 

No. EPA–HQ–OAR–2020–0084. All 

documents in the docket are listed on 

the https://www.regulations.gov 

website. Although listed in the index, 

some information may not be publicly 

available, e.g., Confidential Business 

Information or other information whose 

disclosure is restricted by statute. 

Certain other material, such as 

copyrighted material, is not placed on 

the internet and will be publicly 

available only in hard copy form. All 

other publicly available docket 

materials are available electronically in 

https://www.regulations.gov. Due to 

public health concerns related to 

COVID–19, the EPA Docket Center and 

Reading Room are closed to the public 

with limited exceptions. Our Docket 

Center staff will continue to provide 

remote customer service via email, 

phone, and webform. For further 

information on EPA Docket Center 

services and the current status, please 

visit us online at https://www.epa.gov/ 

dockets. 

FOR FURTHER INFORMATION CONTACT: 

Andy Chang, U.S. Environmental 

Protection Agency, Stratospheric 

Protection Division, telephone number: 

202–564–6658; or email address: 

chang.andy@epa.gov. You may also visit 

our website at https://www.epa.gov/odsphaseout/phaseout-exemptionslaboratory-and-analytical-uses for 

further information. 

SUPPLEMENTARY INFORMATION: 

Throughout this document, whenever 

‘‘we,’’ ‘‘us,’’ or ‘‘our’’ is used, we mean 

EPA. This SUPPLEMENTARY INFORMATION

section is arranged as follows: 

I. What is the background for this action? 

A. What is the Agency’s authority for this 

final action? 

B. Summary of EPA’s Proposed 

Rulemaking and Public Comments 

C. Potentially Impacted Entities 

D. Background of the Laboratory and 

Analytical Use Exemption 

II. What action is EPA taking? 

III. Statutory and Executive Order Reviews 

I. What is the background for this 

action? 

A. What is the Agency’s authority for 

this final action? 

The Clean Air Act (CAA) provides 

EPA the authority to implement the 

Montreal Protocol on Substances that 

Deplete the Ozone Layer’s (Montreal 

Protocol’s) phaseout schedules for 

ozone-depleting substances (ODS) in the 

United States. Relevant to this 

rulemaking, CAA section 604 requires 

EPA to issue regulations phasing out 

production and consumption of class I 1

ODS according to a prescribed schedule; 

our phaseout regulations for class I ODS 

are codified at 40 CFR part 82, subpart 

A. 

B. Summary of EPA’s Proposed 

Rulemaking and Public Comments 

EPA’s August 7, 2020, proposed 

rulemaking (see 85 FR 47940) sought to 

align a provision in EPA’s regulations 

governing the production and import of 

class I ODS regarding the essential 

laboratory and analytical use exemption 

(referred to hereafter as the ‘‘L&A 

exemption’’) with a recent decision 

taken by the Parties to the Montreal 

Protocol to extend the global L&A 

exemption indefinitely.2 In the United 

States, laboratory distributors currently 

supply around 1,000 laboratories, and 

consumption 3 for laboratory use was 

approximately 4.4 ODP-weighted metric 

tons in 2018 under the L&A exemption 4

and 4.2 ODP-weighted metric tons in 

2019 under the L&A exemption.5 The 

global L&A exemption is implemented 

domestically through EPA’s regulations 

at 40 CFR part 82, subpart A and the 

current exemption is in effect in the 

United States through December 31, 

2021. In the proposed rulemaking (85 

FR 47940), EPA proposed to remove the 


jbell on DSKJLSW7X2PROD with RULES
Federal Register / Vol. 86, No. 160 / Monday, August 23, 2021 / Rules and Regulations 46993 

December 31, 2021, time restriction, 

allowing for continued production and 

import of class I ODS in the United 

States after that date for laboratory and 

analytical uses that have not been 

identified by EPA as nonessential. 

During the public comment period for 

the proposed rulemaking, which ended 

on October 6, 2020, EPA received a total 

of two comments which are publicly 

available in the docket. Both comments 

were in support of our proposed action; 

one comment noted that the proposed 

action was a cost- and time-effective 

revision, and the other comment 

supported the notion that laboratories 

could continue to obtain necessary and 

essential materials while being mindful 

of potential environmental impacts. 

EPA acknowledges the comments and 

concludes that they support the final 

action and do not require further 

response. 

C. Potentially Impacted Entities 

This final rule may potentially impact 

individuals or groups that manufacture, 

process, import, or distribute into 

commerce certain ODS and mixtures. 

These impacted entities and their 

associated North American Industrial 

Classification System (NAICS) codes 

may include but are not limited to: 

• Basic chemical manufacturing 

(NAICS code 3251); 

• Pharmaceutical preparations 

manufacturing businesses (NAICS code 

325412); 

• Other chemical and allied 

production merchant wholesalers 

(NAICS code 424690); 

• Environmental consulting services 

(NAICS code 541620); 

• Research and development in the 

physical, engineering, and life sciences 

(NAICS code 54171); and 

• Medical laboratories (NAICS code 

621511). 

This list is not intended to be 

exhaustive; rather, it provides a guide 

for readers regarding entities likely to be 

affected by this final action. The NAICS 

codes provided above may assist in 

determining whether this final rule 

might apply to certain entities. Other 

types of entities not listed could also be 

affected, and EPA recommends that you 

consult the person listed under FOR

FURTHER INFORMATION CONTACT if there 

are applicability questions. 

D. Background of the Laboratory and 

Analytical Use Exemption 

The United States was one of the 

original signatories to the 1987 Montreal 

Protocol and ratified it on April 12, 

1988. After ratification, Congress 

enacted, and President George H.W. 

Bush signed into law, the CAA 

Amendments of 1990, which included 

Title VI on Stratospheric Ozone 

Protection, codified as 42 U.S.C. 

Chapter 85, Subchapter VI, to ensure, 

among other things, that the United 

States could satisfy its obligations under 

the Montreal Protocol. 

The Montreal Protocol is a 

multinational environmental agreement 

to protect Earth’s ozone layer by phasing 

out the consumption and production of 

most chemicals that deplete it. The 

Montreal Protocol provides a set of 

schedules to phase out ODS and also 

provides for mechanisms to establish 

certain specific and limited exemptions. 

For most class I ODS, the Parties to the 

Montreal Protocol may agree to grant 

exemptions to the ban on production 

and consumption of ODS for uses that 

they determine to be ‘‘essential.’’ For 

example, with respect to 

chlorofluorocarbons (CFCs), Article 

2A(4) of the Montreal Protocol provides 

that the phaseout will apply ‘‘save to the 

extent that the Parties decide to permit 

the level of production or consumption 

that is necessary to satisfy uses agreed 

by them to be essential.’’ Similar 

language appears in the control 

provisions for other ODS, such as 

halons (Article 2B), carbon tetrachloride 

(Article 2D), and methyl chloroform 

(Article 2E). As defined by Decision IV/ 

25 of the Parties, ‘‘use of a controlled 

substance should qualify as ‘essential’ 

only if: (1) It is necessary for the health, 

safety or is critical for the functioning of 

society (encompassing cultural and 

intellectual aspects); and (2) there are no 

available technically and economically 

feasible alternatives or substitutes that 

are acceptable from the standpoint of 

environment and health.’’ Decision VI/ 

9 of the Parties established a timelimited exemption under the Montreal 

Protocol for essential laboratory and 

analytical uses, consistent with the 

specifications in Annex II of the report 

of the Sixth Meeting of the Parties 

(MOP), which describes conditions 

applied to the exemption for laboratory 

and analytical uses such as purity, 

quantity, and specification for cylinders 

and handling for these controlled 

substances. 

Consistent with the flexibility allowed 

for by the Parties, in 2001, EPA codified 

a L&A exemption in its domestic 

regulations (see 66 FR 14760, March 13, 

2001). In the preamble to that rule, EPA 

determined that the statutory language 

in section 604 of the CAA provided 

grounds for the creation of a de minimis 

exemption for essential laboratory and 

analytical uses of certain class I ODS 

(id. at 14764–65). The 2001 rule 

explains how the controls in place for 

laboratory and analytical uses provide 

adequate assurance that very little, if 

any, environmental damage will result 

from the handling and disposal of the 

small amounts of class I ODS used in 

such applications due to the Appendix 

G requirements under 40 CFR part 82, 

subpart A, for small quantity and high 

purity. For example, class I ODS must 

be sold in cylinders three liters or 

smaller or in glass ampoules 10 

milliliters or smaller, as per Appendix 

G. Since issuing the original exemption, 

EPA has not received information that 

would suggest that the current controls 

in place for laboratory and analytical 

use do not provide adequate assurance 

that very little, if any, environmental 

damage will result from the handling 

and disposal of class I ODS used in such 

applications. As discussed later in this 

notice, the quantities of class I ODS 

used for this exemption have declined 

substantially since the exemption was 

initially created. 

As summarized in the proposal for 

this final action, the Parties 

subsequently issued several decisions 

related to the global exemption, 

including periodic extensions, and EPA 

has also revised the exemption in its 

domestic regulations several times (see 

85 FR 47941–92, August 7, 2020). Under 

Decision XXVI/5 at the 26th MOP, the 

Parties extended the global L&A 

exemption until December 31, 2021, 

which EPA implemented domestically 

through a rulemaking in 2015 (see 80 FR 

3885, January 26, 2015). More recently, 

in November 2019, at the 31st MOP, the 

Parties agreed in Decision XXXI/5 to 

‘‘extend the global laboratory and 

analytical-use exemption indefinitely 

beyond 2021, without prejudice to the 

parties deciding to review the 

exemption at a future meeting.’’ The 

Decision also encourages parties to 

further reduce their production and 

consumption of ODS for laboratory and 

analytical uses and to facilitate the 

introduction of laboratory standards that 

do not require such substances. 

II. What action is EPA taking? 

EPA is finalizing its August 7, 2020, 

proposal to indefinitely extend the 

global L&A exemption for class I ODS in 

40 CFR 82.8(b). This action makes the 

regulatory exemption indefinite unless 

or until it is limited or eliminated 

through future rulemaking, i.e., EPA 

still has the authority to review the 

scope of and need for the exemption at 

a future date. Upon the effective date of 

this final action, the regulations will no 

longer contain an expiration date for the 

exemption. The list of laboratory and 

analytical uses codified in Appendix G 

to 40 CFR part 82, subpart A, may also 

be revised through new rulemakings as 


jbell on DSKJLSW7X2PROD with RULES
46994 Federal Register / Vol. 86, No. 160 / Monday, August 23, 2021 / Rules and Regulations 

6These data are available in the docket to this 

rule as well as on the Ozone Secretariat’s Data 

Centre web page: https://ozone.unep.org/countries/ 

data-table. 

7These data can now be found on the Montreal 

Protocol’s Ozone Secretariat’s Data Centre web 

page: https://ozone.unep.org/countries/data-table. 

Data specific to the United States’ amounts 

consumed for laboratory and analytical uses, 

including 2019 data, can be found on this web page: 

https://ozone.unep.org/countries/profile/usa. These 

data have been added to the docket for this 

rulemaking. 

alternatives are identified through new 

standards. 

Consistent with the proposal, this 

final action also contains clarifying text 

to explain that the global L&A 

exemption allows for the production 

and import of class I ODS that have 

been phased out in the United States, 

subject to certain restrictions as 

described in Appendix G to 40 CFR part 

82, subpart A, and subject to the 

recordkeeping and reporting 

requirements at 40 CFR 82.13(u) through 

(x). The previous text in 40 CFR 82.8(b) 

established the exemption for essential 

laboratory and analytical uses but did 

not explicitly state that the exemption is 

from the prohibitions on production and 

import of class I ODS, although that is 

clear from context and the explanation 

in a previous rule (see 66 FR 14760, 

March 13, 2001). Consistent with the 

proposal, this final rule states the 

exemption more explicitly. 

As noted in the proposed rule, there 

are several reasons why the Agency is 

making these changes. This action is 

consistent with Decision XXXI/5 by the 

Parties to the Montreal Protocol, and it 

will provide certainty with regards to 

the exemption without the need for 

periodic rulemakings to extend the 

exemption. This is important since nonODS replacements for class I ODS may 

not be identified for all uses given the 

effort required to establish new 

analytical procedures for such small 

quantities of material. While some 

analytical procedures have transitioned, 

many ASTM International (formerly 

known as the American Society for 

Testing and Materials) and ISO 

(International Organization for 

Standardization) standards still require 

small amounts of ODS, and it could take 

years for standards organizations to 

develop alternatives and for laboratories 

to adopt the new standards. 

From an environmental impact 

perspective, removing the deadline from 

the L&A exemption will also have little 

effect on the stratospheric ozone layer 

due to a combination of factors 

including the general decline of 

production and consumption of ODS for 

laboratory and analytical uses in the 

United States and the existing controls 

in place for laboratory and analytical 

uses. 

Exempted consumption for laboratory 

and analytical uses in the United States 

peaked in 2004 at 55 ODP-weighted 

metric tons, and was only 4.4 ODPweighted metric tons in 2018, which is 

a negligible amount.6 Data for 2019, 

which became available after the 

publication date for EPA’s proposed 

rulemaking, indicates that the exempted 

consumption for laboratory and 

analytical uses in the United States has 

decreased further to 4.2 ODP-weighted 

metric tons.7 This sharp decline since 

2004 indicates that many users 

(primarily laboratories) have been able 

to transition from ODS even with this 

exemption being available to them; as 

these laboratories continue to use nonODS and/or continue to transition to 

non-ODS alternatives for laboratory and 

analytical uses, EPA anticipates that the 

decreasing trend for class I ODS for 

exempted consumption will generally 

continue. However, certain laboratory 

and analytical procedures continue to 

require the use of class I ODS in the 

United States. In the United States, 

there are currently ten laboratory 

distributors that supply around 1,000 

laboratories with primarily carbon 

tetrachloride but also small quantities of 

chlorobromomethane, CFCs, methyl 

chloroform, and methyl bromide. 

Maintaining this exemption would 

provide laboratories with essential class 

I ODS for which no alternatives are 

currently available, with negligible 

environmental impacts. 

Additionally, this action does not 

make any change in the controls that are 

in place for laboratory and analytical 

uses, and as discussed above in the 

section titled, ‘‘Background of the 

Laboratory and Analytical Use 

Exemption,’’ EPA’s March 13, 2001, rule 

explains how these controls provide 

adequate assurance that very little, if 

any, environmental damage will result 

from the handling and disposal of small 

amounts of class I ODS used in such 

applications. Further, EPA has the 

authority to review the scope of and 

need for the exemption at a future date, 

for example if alternative methods 

become available or consumption begins 

to increase. Lastly, as noted earlier in 

this notice, we received two supportive 

comments and no adverse comments on 

the proposed rule associated with this 

final action. Based on consideration of 

all this information and the two 

comments that both supported the 

proposed rule, EPA is finalizing the 

action as proposed. 

EPA encourages laboratories to 

continue ongoing efforts to transition to 

methods that do not require the use of 

ODS, and to share such information 

when available, as it could assist others 

in similar situations. 

III. Statutory and Executive Order 

Reviews 

A. Executive Order 12866: Regulatory 

Planning and Review and Executive 

Order 13563: Improving Regulation and 

Regulatory Review 

This action is not a significant 

regulatory action and was therefore not 

submitted to the Office of Management 

and Budget (OMB) for review. 

B. Paperwork Reduction Act (PRA) 

This action does not impose any new 

information collection burden under the 

PRA. OMB has previously approved the 

information collection activities 

contained in the existing regulations 

and has assigned OMB control number 

2060–0170. The laboratory and 

analytical use exemption currently 

expires on December 31, 2021, and this 

action allows for continued production 

and import of class I substances in the 

United States solely for laboratory and 

analytical uses that have not been 

identified by EPA as nonessential, and 

therefore there are no PRA implications. 

This action indefinitely removes the 

expiration date for the existing 

exemption from the prohibitions in 

production and import of class I ODS. 

C. Regulatory Flexibility Act (RFA) 

I certify that this action will not have 

a significant economic impact on a 

substantial number of small entities 

under the RFA. This action does not 

modify the recordkeeping and reporting 

requirements that apply to laboratory 

distributors who utilize the exemption. 

These requirements will continue to 

apply to distributors who use the 

exemption; however, the requirements 

are minimal and impose no significant 

burden. Further, nothing in this rule 

compels any entity to use the 

exemption. The Agency thus assumes 

that the burden reduction provided by 

the exemption from the phaseout on 

production and import of class I ODS 

outweighs the limited cost associated 

with recordkeeping and reporting. 

Otherwise, laboratory distributors could 

choose not to use the exemption, 

removing the need for relevant 

recordkeeping and reporting. 

D. Unfunded Mandates Reform Act 

(UMRA) 

This action does not contain any 

unfunded mandate as described in 

UMRA, 2 U.S.C. 1531–1538, and does 


jbell on DSKJLSW7X2PROD with RULES
Federal Register / Vol. 86, No. 160 / Monday, August 23, 2021 / Rules and Regulations 46995 

not significantly or uniquely affect small 

governments. The action imposes no 

enforceable duty on any state, local, or 

tribal governments or the private sector. 

E. Executive Order 13132: Federalism 

This action does not have federalism 

implications. It will not have substantial 

direct effects on the states, on the 

relationship between the national 

government and the states, or on the 

distribution of power and 

responsibilities among the various 

levels of government. 

F. Executive Order 13175: Consultation 

and Coordination With Indian Tribal 

Governments 

This action does not have tribal 

implications as specified in Executive 

Order 13175. It will not have substantial 

direct effects on tribal governments, on 

the relationship between the federal 

government and Indian tribes, or on the 

distribution of power and 

responsibilities between the federal 

government and Indian tribes, as 

specified in Executive Order 13175. 

Thus, Executive Order 13175 does not 

apply to this action. EPA periodically 

updates tribal officials on air regulations 

through the monthly meetings of the 

National Tribal Air Association and will 

share information on this rulemaking 

through this and other fora. 

G. Executive Order 13045: Protection of 

Children From Environmental Health 

Risks and Safety Risks 

This action is not subject to Executive 

Order 13045 because it is not 

economically significant as defined in 

Executive Order 12866, and because 

EPA does not believe the environmental 

health or safety risks addressed by this 

action present a disproportionate risk to 

children. Depletion of stratospheric 

ozone results in greater transmission of 

the sun’s ultraviolet (UV) radiation to 

the earth’s surface. The following 

studies describe the effects of excessive 

exposure to UV radiation on children: 

(1) Westerdahl J, Olsson H, Ingvar C. 

‘‘At what age do sunburn episodes play 

a crucial role for the development of 

malignant melanoma,’’ Eur J Cancer 

1994; 30A:1647–54; (2) Elwood JM, 

Japson J. ‘‘Melanoma and sun exposure: 

An overview of published studies,’’ Int 

J Cancer 1997; 73:198–203; (3) 

Armstrong BK. ‘‘Melanoma: Childhood 

or lifelong sun exposure,’’ In: Grobb JJ, 

Stern RS, Mackie RM, Weinstock WA, 

eds. Epidemiology, causes and 

prevention of skin diseases (pp 63–66), 

London: Blackwell Science, 1997; (4) 

Whiteman D, Green A. ‘‘Melanoma and 

Sunburn,’’ Cancer Causes Control, 1994; 

5:564–72; (5) Heenan, PJ. ‘‘Does 

intermittent sun exposure cause basal 

cell carcinoma? A case control study in 

Western Australia,’’ Int J Cancer 1995; 

60:489–94; (6) Gallagher RP, Hill GB, 

Bajdik CD, et al. ‘‘Sunlight exposure, 

pigmentary factors, and risk of 

nonmelanocytic skin cancer I, Basal cell 

carcinoma,’’ Arch Dermatol 1995; 

131:157–63; (7) Armstrong, BK. ‘‘How 

sun exposure causes skin cancer: An 

epidemiological perspective,’’ In: Hill D, 

Elwood JM, English DR (eds.) 

Prevention of Skin Cancer. Cancer 

Prevention—Cancer Causes, vol. 3 (pp 

89–116). Dordrecht: Springer, 2004. 

However, as described in the section 

above titled ‘‘What Action is EPA 

Taking?’’, the environmental impacts 

are expected to be negligible. 

H. Executive Order 13211: Actions That 

Significantly Affect Energy Supply, 

Distribution, or Use 

This action is not subject to Executive 

Order 13211, because it is not a 

significant regulatory action under 

Executive Order 12866. 

I. National Technology Transfer and 

Advancement Act (NTTAA) 

This rulemaking does not involve 

technical standards. 

J. Executive Order 12898: Federal 

Actions To Address Environmental 

Justice in Minority Populations and 

Low-Income Populations 

The environmental impacts of this 

regulation are expected to be negligible 

given the low level of ODS produced 

and imported for the L&A exemption. 

As such, there are no disproportionately 

high and adverse human health or 

environmental effects from this action 

on minority populations, low-income 

populations, and/or indigenous peoples, 

as specified in Executive Order 12898 

(59 FR 7629, February 16, 1994). 

K. Congressional Review Act 

This action is subject to the 

Congressional Review Act, and EPA will 

submit a rule report to each House of 

the Congress and to the Comptroller 

General of the United States. This action 

is not a ‘‘major rule’’ as defined by 5 

U.S.C. 804(2). 

List of Subjects in 40 CFR Part 82 

Environmental protection, 

Administrative practice and procedure, 

Air pollution control, Chemicals, 

Chlorofluorocarbons, Imports, Methyl 

chloroform, Ozone, Reporting and 

recordkeeping requirements. 

Michael S. Regan, 

Administrator. 

For the reasons set out in the 

preamble, 40 CFR part 82 is amended as 

follows: 

PART 82—PROTECTION OF 

STRATOSPHERIC OZONE 

■ 1. The authority citation for part 82 

continues to read as follows: 

Authority: 42 U.S.C. 7414, 7601, 7671– 

7671q. 

■ 2. Section 82.8 is amended by revising 

paragraph (b) to read as follows: 

§ 82.8 Grant of essential use allowances 

and critical use allowances. 

* * * * * 

(b) There is a global exemption for the 

production and import of class I 

controlled substances for essential 

laboratory and analytical uses, subject to 

the restrictions in appendix G of this 

subpart, and subject to the 

recordkeeping and reporting 

requirements at § 82.13(u) through (x). 

There is no amount specified for this 

exemption. 

* * * * * 

[FR Doc. 2021–17745 Filed 8–20–21; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL COMMUNICATIONS 

COMMISSION 

47 CFR Parts 1 and 54 

[WC Docket No. 18–89; FCC 21–86; FR ID 

41783] 

Protecting Against National Security 

Threats to the Communications Supply 

Chain Through FCC Programs 

AGENCY: Federal Communications 

Commission. 

ACTION: Final rule. 

SUMMARY: In this document, the Federal 

Communications Commission 

(Commission) adopts rules to modify 

the Secure and Trusted 

Communications Networks 

Reimbursement Program 

(Reimbursement Program) consistent 

with the Secure and Trusted 

Communications Networks Act of 2019, 

as modified by the Congressional 

Appropriations Act, 2021. 

DATES: Effective October 22, 2021. 

FOR FURTHER INFORMATION CONTACT: 

Brian Cruikshank, Wireline Competition 

Bureau, brian.cruikshank@fcc.gov, 202– 

418–3623 or TTY: 202–418–0484. 


jbell on DSKJLSW7X2PROD with RULES